Autopsy report · NCT03219372
Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
Cause of deathSlow enrollment
“Study discontinued due to low accrual.”
Life of this trial
- Registered 1 year 2 months before it started.
- Ran for about 5 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 1 year 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Cedars-Sinai Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Hepatocellular Carcinoma; Liver Cirrhoses
- Interventions
- Pravastatin Pill; Placebo Oral Tablet
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
“Study stopped due to low accrual.” - Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
“Study discontinued due to futility.” - Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
“The study was terminated due to low accrual.” - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
“Study terminated due to low accrual.” - Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast
“Study discontinued due to lack of subject follow-up.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.